Thryv Therapeutics Announces JACC: Heart Failure Publication of Converging Human Genetic, Preclinical, and Clinical Evidence Supporting Phase 2a Development of Lead SGK1 Inhibitor THRV-1268 in Heart Failure
Summary
Thryv Therapeutics announced a JACC publication presenting converging genetic, preclinical, and clinical evidence supporting Phase 2a development of THRV-1268, an SGK1 inhibitor for heart failure. The lead compound demonstrated favorable Phase 1 safety profile and outperformed empagliflozin in validated heart failure models.
Clinical Trial Data
Phase 1 and Phase 2a
Met
Outcome Details
JACC publication of converging human genetic, preclinical, and clinical evidence supporting Phase 2a development. THRV-1268 maintained near-normal ejection fraction and outperformed empagliflozin monotherapy in validated heart failure model. Phase 1 studies demonstrated favorable safety profile and QTcF shortening.
Read the original article
Published by PR Newswire Clinical Trials on September 15, 2026 2:41 PM